Kymera Therapeutics KYMR Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kymera Therapeutics's contract liabilities?
- Kymera Therapeutics (KYMR) reported contract liabilities of $0 in Q1 2026.
- What is the long-term trend for Kymera Therapeutics's contract liabilities?
- Over 5 years (2020 to 2025), Kymera Therapeutics's contract liabilities has grown at a -31.9% compound annual growth rate (CAGR), from $77.84M to $11.44M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.